Roth MKM lowered the firm’s price target on Bio-Path (BPTH) to $9 from $12 and keeps a Buy rating on the shares. The company ended Q4 with $1.2M in cash, indicating Bio-Path requires near-term financing, the analyst tells investors. Additionally, there were no material pipeline updates in its quarterly earnings beyond those released last month, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPTH: